Physician profile
Christopher Thomas Lee
NPI 1932426491
$3,095.94
in general payments reported to CMS, 2019-2025
25 companies · $514 in 2025
The $514 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $231 · 2020: $153 · 2021: $485 · 2022: $442 · 2023: $438 · 2024: $832 · 2025: $514.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,685 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,685.03 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $537.14 | 2022-2025 | |
| Optinose US, INC. | $398.56 | 2019-2025 | |
| Kaleo, INC. | $360.59 | 2019-2023 | Auvi-Q |
| Sanofi-Aventis U.S. LLC | $255.08 | 2020-2024 | |
| Inspire Medical Systems, INC. | $206.86 | 2024-2025 | Inspire |
| Glaxosmithkline, LLC. | $197.03 | 2024 | Nucala |
| Regeneron Healthcare Solutions, INC. | $195.50 | 2021-2025 | Dupixent |
| Cumberland Pharmaceuticals, INC. | $140.79 | 2023-2025 | Caldolor |
| Stryker Corporation | $139.94 | 2019-2025 | Scopis Ent, Audion Et Dilation System |
| Medtronic, INC. | $103.65 | 2023-2025 | Propel, Stealthstation S8 Platform |
| Arrinex, INC. | $76.19 | 2019 | |
| Aerin Medical INC. | $75.25 | 2024 | |
| Amgen INC. | $74.20 | 2024-2025 | Krystexxa, Tezspire |
| Alk-Abello, INC | $48.91 | 2019-2021 | |
| Karl Storz Endoscopy-America | $47.19 | 2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $43.74 | 2020-2024 | Tula |
| Olympus America INC. | $30.67 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $29.27 | 2021-2023 | |
| Acclarent, INC | $29.21 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.68 | 2025 | Eohilia |
| Photonicare INC | $23.52 | 2023 | Otosight Middle Ear Scope |
| Xoran Technologies LLC | $15.64 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $15.20 | 2025 | Exparel |
| Glenmark Therapeutics INC. | $14.00 | 2019 | |
| Integra Lifesciences Corporation | $12.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.